The transcriptional co-activator PGC-1α is recognized as the master regulator of 24 mitochondrial biogenesis. However, recently a novel isoform, PGC-1α4 that specifically 25 regulates muscle hypertrophy was discovered. Since stimulation of mTORC1 activity is 26 tightly coupled to hypertrophy, we hypothesized that activation of this pathway would 27 upregulate PGC-1α4. Eight male subjects performed heavy resistance exercise (10 x 8-12 28 repetitions at ~75% of 1RM in leg press) on four different occasions, ingesting in random 29 order a solution containing essential amino acids (EAA), branched-chain amino acids 30 (BCAA), leucine or flavored water (placebo) during and after the exercise. Biopsies were 31 taken from the vastus lateralis muscle before and immediately after exercise, as well as 32 following 90 and 180 min of recovery. Signaling through mTORC1, as reflected in S6K1 33 phosphorylation, was stimulated to a greater extent by the EAA and BCAA than the 34 leucine or placebo supplements. Unexpectedly, intake of EAA or BCAA attenuated the 35 stimulatory effect of exercise on PGC-1α4 expression by ~50% (from a 10-fold to 5-fold 36 increase with BCAA and EAA, P<0.05) 3 h after exercise, whereas intake of leucine alone 37 did not reduce this response. The 60% increase (P<0.05) in the level of PGC-1α1 mRNA 38 90 min after exercise was uninfluenced by amino acid intake. Muscle glycogen levels were 39 reduced and AMPKα2 activity and phosphorylation of p38 MAPK enhanced to the same 40 extent with all four supplements. In conclusion, induction of PGC-1α4 does not appear to 41 regulate the nutritional (BCAA or EAA) mediated activation of mTORC1 in human 42 muscle. 43 44
was homogenized in ice-cold buffer (100 µl mg -1 dry weight) containing 2 mM HEPES 147 (pH 7.4), 1 mM EDTA, 5 mM EGTA, 10 mM MgCl 2 , 50 mM β-glycerophosphate, 1%was then rotated for 30 min at 4ºC and subsequently centrifuged for 10 min at 10,000 g and 152
4°C
. After dilution of part of the supernatant (1:10 in distilled water), its protein 153 concentration was determined using the Pierce TM 660 nm protein assay (Thermo Scientific, 154
Rockford, USA) and the remainder of the supernatant then stored at -80°C until further 155
analysis. 156
The immunoblot analysis employed has been described in detail earlier (2) . 157
Briefly, aliquots of muscle homogenates were diluted in Laemmli sample buffer (Bio-Rad 158
Laboratories, Richmond, CA, USA), the proteins separated by SDS-PAGE, transferred to 159 PVDF membranes and incubated with the following antibodies: primary antibodies against 160 S6K1 (Thr 389 , #9234; total #2708), p38 (Thr 180 /Tyr 182 , #4511; total, #9212) and CamKII 161 (Thr 286 , #12716; total, #4436) were purchased from Cell Signaling Technology (Beverly, 162 MA, USA). All primary antibodies were diluted 1:1000. Secondary anti-rabbit (#7074) 163 antibody (1:10000) was purchased from Cell Signaling Technology. Proteins were 164 visualized by applying Super Signal West Femto Chemiluminescent Substrate (Thermo 165 Scientific), followed by detection on a Molecular Imager ChemiDoc XRS system and 166 quantified utilizing the contour tool in the Quantity One v. 4.6.3 software (Bio-Rad 167 Laboratories). Subsequently, the membranes were stripped using Restore Western Blot 168
Stripping Buffer (Thermo Scientific) for 30 min at 37°C, and then reprobed with primary 169 antibodies for each respective total protein. The levels of all phosphoproteins were 170 normalized to the total level of the same protein. 
Analysis of muscle glycogen and plasma amino acid and insulin concentrations 182
Muscle glycogen was determined according to the method described by Leighton and 183 coworkers (15). Amino acid concentration in plasma was analysed according to Bornø and 184 van Hall (6) using liquid chromatography tandem mass spectrometry in a subset of 185 samples. Levels of plasma insulin were measured using an ELISA kit (Mercodia, Uppsala, 186 Sweden) in accordance with the manufacturer's instructions. 187
188

RNA extraction and quantitative Real-Time RT-PCR 189
From approximately 3 mg freeze-dried muscle tissue, total RNA was extracted by 190 homogenization in PureZOL RNA isolation reagent (Bio-Rad Laboratories) employing the 191
BulletBlender and RNAse-free ZrO beads (0.5 mm). The concentration and purity of the 192 RNA was determined using a NanoDrop TM Lite (Thermo Scientific) and 2 μg RNA was 193 used for reverse transcription of 40 μl cDNA with iScript cDNA Synthesis Kit (Bio-Rad 194 Laboratories). The mean 260/280 nm ratio of the RNA was 1.87 in purified water and the 195 mean concentration 183 µg • ml -1 . 196
water. Samples were run in triplicate and all samples from each subject were run on the 201 same plate to allow direct relative comparisons. Relative changes in mRNA expression for 202 the genes of interest were quantified by 2 -ΔCt (31). 203
The validity of GAPDH mRNA as an internal control has been confirmed in a 204 previous study (5). In accordance to this, no changes in absolute Ct for GAPDH were 205 In the following discussion, we have chosen to use the term PGC-1α when studies 209 are cited that do not distinguish between different isoforms. 210
211
Statistical analyses 212
Parametric statistical procedures were applied to obtain means and standard errors of the 213 mean (SE), which, unless otherwise indicated, are the values presented in the text. A two-214 way (time x supplement) repeated measures ANOVA was used to compare alterations in 215 gene expression, intracellular signaling, kinase activity and levels of glycogen and amino 216 acids. The area under the insulin-time curve in the four conditions was compared using a 217 one-way ANOVA. Whenever a significant main or interaction effect was observed, a 218
Fisher's LSD post hoc test was performed. All statistical analyses were performed with the 219 STATISTICA software (version 12.0, StatSoft, Inc., Tulsa, USA), and P<0.05 was 220 considered statistically significant. 221
Seven subjects performed exactly the same amount of work in the four trials, whereas one 225 subject performed one repetition less in two of the trials. The subjects performed 103 ± 6 226 repetitions in the 10 sets. 227 228
Effects of exercise and intake of amino acids on the levels of PGC-1α mRNA in muscle 229
Resistance exercise induced a pronounced increase in the level of PGC-1α4 mRNA, but 230 only a minor elevation of PGC-1α1 mRNA ( Fig. 1 ). This is in agreement with some 231 previous reports (27, 29) , but in contrast to another (33). Moreover, both isoforms were 232 elevated 90 min after exercise, PGC-1α1 by ~60% and PGC-1α4 by 3-to 5-fold (P<0.05 in 233 both cases), but only the expression of PGC-1α4 was further elevated (10-fold; P<0.05) at 234 180 min of recovery. 235
Intake of leucine alone did not influence the exercise-induced changes in 236 expression of PGC-1α4 mRNA, whereas ingestion of BCAA and EAA markedly 237 suppressed the elevation after 180 min of recovery (P<0.05 for both EAA and BCAA in 238 comparison to both placebo and leucine) (Fig. 1) . Moreover, the 3-to 5-fold enhancement 239 in the level of PGC-1α4 mRNA 90 min after exercise was unaffected by amino acid intake 240 (Fig. 1B) . At the same time, intake of BCAA and EAA did not influence the small, but 241 significant elevation in PGC-1α1 mRNA (Fig. 1A) . These divergent responses to 242 resistance exercise, together with the differing sensitivities of the isoforms to intake of 243 BCAA and EAA, indicate that they are regulated differently and play different roles in 244 adaptation to training. 245 S6K1, was elevated to larger extent by EAA (2) and BCAA (14) than by leucine or 249 placebo, respectively. Although this effect of EAA was larger than with BCAA following 250 90 min of recovery, the increases in phosphorylation were similar (7-to 8-fold) 180 min 251 after exercise ( Fig. 2A) . In disagreement with our hypothesis, this stimulation of mTORC1 252 by amino acids was not associated with an elevated level of PGC-1α mRNA; instead the 253 PGC-1α4 response was reduced by 50% and that of PGC-1α1 unaffected by ingestion of 254
BCAA and EAA. 255
In light of previous indications of a positive relationship between mTOR and 256 PGC-1α in mice skeletal muscle (8), this latter observation was unexpected. However, in a 257 recent study, administration of rapamycin to mice was found to amplify the increase in 258 PGC-1α mRNA caused by one hour of running, suggesting an inverse relationship 259 between mTOR activity and PGC-1α (23). Nonetheless, the lack of any effect of leucine 260 alone on the PGC-1α4 response, despite its stimulatory effect on mTORC1 signaling (Fig.  261 2A), suggests that there is no interaction between these two processes in human muscle. 262
Alternatively, there may be a threshold level above which mTORC1 activation suppresses 263 PGC-1α4 expression, which in the leucine trial was not attained. 264 265
Alterations in upstream kinases capable of activating PGC-1α 266
Exercise activates a number of signaling pathways, including those involving AMPK and 267 p38 MAPK that contribute to the acute induction of PGC-1α (1, 12). Here, the activity of 268 AMPKα1 was not influenced by exercise, whereas AMPKα2 activity was elevated an 269 average of 135% (P<0.05) (Fig. 2B, D) , in agreement with a previous finding (10).
(average 536 mmol kg -1 dry muscle), as was the decrease during exercise (22-30%; 280 P<0.05) (Fig. 3) . This would appear to rule out this factor as a potential mediator of the 281 attenuated PGC-1α4 response associated with ingestion of BCAA or EAA. Previous 282 observations raise the possibility that muscle glycogen and activation of AMPK and p38 283 MAPK induce PGC-1α1 rather than PGC-1α4 mRNA (19) and importantly, the level of 284 mRNA encoding the former isoform was, in fact, not influenced by intake of amino acids 285 (Fig. 1A) . 286
The plasma level of leucine was increased to a similar extent (~30%) during 287 exercise by ingestion of leucine alone, BCAA or EAA. The level increased even further 288 and remained elevated throughout the recovery period (Fig. 4A) . The levels of isoleucine 289 and valine were elevated by the BCAA and EAA supplements, but fell in the placebo and 290 leucine trials (Fig. 4B, C) . The level of BCAA rose to the same extent when BCAA and 291 EAA were ingested, but fell 25% in the placebo and leucine trials (Fig. 2D) . Changes in 292 plasma levels of these amino acids largely reflect changes in muscle levels (20). Hence, 293 these observations suggest that the muscle level of BCAA may be related to the attenuated 294 exercise-induced stimulation of PGC-1α4 expression, but, the potential underlying 295 mechanism remains unclear.
the period pre-exercise to 90 min post-exercise, was larger when EAA was ingested as 298 compared to both placebo and leucine, whereas the release following BCAA intake 299 differed significantly compared to placebo but not to leucine (Fig. 5) . Although there was 300 no difference between the EAA and BCAA trials, the lack of difference between the 301 BCAA and leucine trials, despite a 50% reduction of PGC-1α4 expression with the former 302 supplement do not support an involvement of insulin in the attenuated response of PGC-303 1α4 to resistance exercise. 304
In summary, intake of a mixture of BCAA or EAA attenuated the elevation in the 305 level of PGC-1α4 mRNA caused by resistance exercise, but had no effect on PGC-1α1 306
expression. Although the significance of this attenuation is not yet known, this difference 307
does reveal differential regulation of the two isoforms. The attenuation of the PGC-1α4 308 response was not related to activation of AMPK, p38 MAPK or to glycogen availability, 309 since these factors changed to the same extent regardless of supplement. These 310 observations raise the possibility that these factors induce PGC-1α1 rather than PGC-1α4 311 mRNA. Moreover, based on the differential response to ingestion of leucine alone in 312 comparison to BCAA or EAA, induction of PGC-1α4 does not appear to influence the 313 stimulation of mTORC1 signaling. It is therefore possible that PGC-1α4 regulates muscle 314 growth through interaction with other signaling pathways. 315
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